Skip to Content

Virtus KAR Health Sciences C RCGHX

Medalist Rating as of | See Virtus Investment Hub
  • NAV / 1-Day Return 17.00  /  −0.58 %
  • Total Assets 141.0 Mil
  • Adj. Expense Ratio
    2.140%
  • Expense Ratio 2.140%
  • Distribution Fee Level Above Average
  • Share Class Type Level Load
  • Category Health
  • Investment Style Large Growth
  • Min. Initial Investment 2,500
  • Status Open
  • TTM Yield
  • Turnover 75%

USD | NAV as of Apr 17, 2024 | 1-Day Return as of Apr 17, 2024, 11:53 PM GMT+0

Morningstar’s Analysis RCGHX

Will RCGHX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Strength in Virtus KAR Health Sciences C's People Pillar is partially offset by an Average Process Pillar rating, leading to a Morningstar Medalist Rating of Neutral.

null Morningstar Manager Research

Morningstar Manager Research

Summary

Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the highest quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings RCGHX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 49.6
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

9.33 13.2 Mil
Healthcare

UnitedHealth Group Inc

5.46 7.7 Mil
Healthcare

IDEXX Laboratories Inc

4.85 6.9 Mil
Healthcare

AbbVie Inc

4.75 6.7 Mil
Healthcare

The Cooper Companies Inc

4.74 6.7 Mil
Healthcare

Zoetis Inc Class A

4.44 6.3 Mil
Healthcare

Merck & Co Inc

4.11 5.8 Mil
Healthcare

Vertex Pharmaceuticals Inc

4.06 5.7 Mil
Healthcare

West Pharmaceutical Services Inc

3.96 5.6 Mil
Healthcare

Danaher Corp

3.86 5.5 Mil
Healthcare